Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed, S-1, and Bevacizumab in Refractory mCRC
NCT03843853Phase 2Withdrawn
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed in metastatic colorectal cancer (mCRC), sponsored by Jiangsu Provincial People's Hospital. Planned start May 2019; status: withdrawn.
02
Drugs
pemetrexed
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03843853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843853.